ONWARD Medical has secured exclusive rights to integrate the WIMAGINE brain-computer interface (BCI) technology, developed by CEA researchers at Clinatec, into its own ARC-BCI™ system. This agreement positions the company to potentially launch the first market-ready BCI-activated system designed to restore movement through thought for individuals with paralysis.
The WIMAGINE technology, a key innovation from the French Atomic Energy and Alternative Energies Commission (CEA), will now be exclusively licensed to ONWARD for this application. The integration aims to combine WIMAGINE's neural signal recording capabilities with ONWARD's ARC-BCI platform, which delivers targeted spinal cord stimulation.
This strategic licensing deal accelerates ONWARD's pathway to commercializing a complete, implantable BCI system. The goal is to enable thought-controlled movement restoration, representing a significant advance in neurotechnology for paralysis treatment.